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Alopecia areata (AA) is a prevalent
autoimmune disease characterized by
an aberrant immune response targeted
to the hair follicle. A lack of under-
standing of the molecular basis of dis-
ease has been an impediment to the
development of therapeutic in-
terventions and perpetuates an unmet
medical need for patients (Delamere
et al., 2008). Our first genome-wide
association study (GWAS) identified
eight regions in the genome with sta-
tistically significant evidence for asso-
ciation, the majority of which had not
been previously associated with AA.
Unexpectedly, this study also revealed
associations shared with other autoim-
mune diseases such as type 1 diabetes
and rheumatoid arthritis (Petukhova
et al., 2010), providing an initial ratio-
nale for drug repositioning of Janus ki-
nase (JAK) inhibitors, which we
subsequently validated biologically
with immunological and pharmaco-
logical studies in the C3H/HeJ AA
mouse model and in human patients
with AA (Xing et al., 2014).
We recently published our first meta-
analysis GWAS in AA in which we
tested up to 1.2 million single nucleotide
polymorphisms (SNPs) for disease asso-
ciation in a cohort of unrelated in-
dividuals, including 3,253 cases and
7,543 controls (Betz et al., 2015). This
study identified additional associations
and increased the total number of asso-
ciated regions to 14. The associated
linkage disequilibrium blocks span
across protein-coding genes and regula-
tory features that can influence the
expression of genes in adjacent regions.
A major challenge in the translation
of GWAS evidence into disease mech-
anism is to determine which gene or set
of genes at or near an associated link-
age disequilibrium block are making
etiological contributions to disease.
Recent systems biology approaches toAbbreviations: AA, alopecia areata; GO, gene ontolo
single nucleotide polymorphism
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demonstrate that chromatin state is an
important determinant of gene expres-
sion, by rendering specific genomic
regions accessible to the transcriptional
machinery. Transcription factors in turn
provide specificity to gene expression
signatures emanating from an acces-
sible locus in particular tissues, result-
ing in cell-specific repertoires of gene
expression. Thus, functionally related
genes may be found in physical prox-
imity within the genome, but a given
disease-associated locus may contain
genes without etiological importance.
This aspect of genome biology provides
a rationale for assessing functional
themes across GWAS loci, providing
insight into disease mechanisms and
guiding future research efforts by iden-
tifying particular genes that could be
acting as conduits between association
evidence and disease pathogenesis.
Pathway and network analyses are
analytic methods that can generate
specific mechanistic hypotheses by
identifying sets of genes participating
in common physiological processes.
To better understand the biological
implications of the AA GWAS statis-
tical evidence, in this study we char-
acterized functional patterns in genes
across the GWAS loci by employing
pathway analysis, gene ontology
(GO) term enrichment analysis, and
protein-protein interaction network
construction.
We first compiled a list of protein-
coding genes located within a 1 Mb
window centered on the most signifi-
cant SNP within each of the 14 GWAS
loci (Table 1) using BioMart Ensembl
(Smedley et al., 2015), and identified
225 genes (Supplementary Table S1
online). We chose to use a 1 Mb
window because chromatin capture
experiments have identified autoim-
mune GWAS SNPs located within re-
gions that engage in long-rangegy; GWAS, genome-wide association study; SNP,
015
e 136interactions, interacting with genes, on
average, located 118 kb away.
Although these loops can range up to
1.5 Mb, a window of 1 Mb would
capture 98% of interactions reported
for autoimmune GWAS SNPs (Mifsud
et al., 2015). We included the HLA in
this analysis, because this locus dem-
onstrates among the most robust GWAS
evidence. Furthermore, although this
region of the genome is both gene
dense and exhibits long-range linkage
disequilibrium confounding interpreta-
tion of association evidence, these
features augment power to detect
disease-relevant relationships in
pathway analyses.
For pathway and GO term analyses,
the list of protein-coding genes at AA
GWAS loci was uploaded to the Data-
base for Annotation, Visualization and
Integrated Discovery (Huang da et al.,
2009). Database for Annotation, Visu-
alization and Integrated Discovery an-
notated 207 of the 225 genes,
and included them in analyses
(Supplementary Table S1). Twenty-
seven pathways were then identified
that are significantly enriched by genes
at AA GWAS loci (Supplementary
Table S2 online). Thirty-one genes
from eight loci contributed to this evi-
dence (Table 1 and Supplementary
Table S1). All of these pathways
involve immune system processes or
immune-related diseases. Among these
are antigen processing and presentation
(P ¼ 2.6  1012), the costimulatory
pathway (P ¼ 1.3  105), and JAK-
STAT (signal transducer and activator
of transcription) signaling (P ¼ 9.4 
104). It is interesting that one of the
highest comorbidities among patients
with AA is included among enriched
disease-related pathways: autoimmune
thyroid disease (P ¼ 3.1  1017).
Some pathways with significant evi-
dence for enrichment are not obviously
related to disease if we consider
only their title, such as intestinal IgA
production (P ¼ 3.9  1019), asthma
(P ¼ 2.3  1018), and viral myocarditis
(P ¼ 1.1  1009). However,
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Petukhova and Christiano
Pathway Analysis of GWAS Loci in Alopecia Areataunderlying shared biological processes
could be driving these results. For
example, antibody production, Th2
signatures, and innate immune re-
sponses are shared respectively be-
tween these diseases and AA.
An analysis of GO terms with Data-
base for Annotation, Visualization and
Integrated Discovery revealed 81 bio-
logical processes enriched by protein-
coding genes at AA GWAS loci
(Supplementary Table S3 online). This
evidence was driven by 83 genes across
all 14 loci (Table 1). Similar to pathway
analysis, many immune-related pro-
cesses were implicated by this analysis,
including antigen processing and pre-
sentation (GO:0019882; P ¼ 9.7 
1021), regulation of T-cell activation
(GO:0050863; P ¼ 1.5  105) and
differentiation (GO:0045580; P ¼
4.1  104), and regulation of the JAK-
STAT signaling cascade (GO:0046425;
P ¼ 0.01).
Gene mapping in Mendelian disor-
ders has demonstrated that genes un-
derlying the same disease often encode
proteins that physically interact.
DAPPLE is a computational tool that
constructs protein-protein interaction
networks from genes that are associ-
ated with complex disease by drawing
from curated protein interaction data-
bases (Rossin et al., 2011). DAPPLE
identified 46 proteins from 13 AA
GWAS loci that physically interact
(Table 1). Allowing the program to add
in a single connecting protein creates
a single highly connected network
(P ¼ 0.002) of 148 GWAS genes
from across all 14 loci (Figure 1;
Supplementary Table S1).
Because the goal of this study is to
identify disease-relevant processes
revealed by GWAS evidence, we
chose to include the HLA in this
analysis. To empirically determine the
effects of including this gene-dense
region in our analysis, we repeated
GO term enrichment and pathway
analyses in Database for Annotation,
Visualization and Integrated Discov-
ery excluding the HLA and found
that P-values were not substantially
different for the vast majority of
results and our most clinically rele-
vant findings, which support the
involvement of JAK-STAT signaling
and costimulatory response, remain
significant.www.jidonline.org 315
Figure 1. PPI network of AA GWAS genes. We uploaded 226 AA GWAS genes into DAPPLE, a web-based computer program that identifies protein-protein
interactions among sets of genes. Allowing the program to add in a single connecting protein (gray nodes) creates a single highly connected network (P ¼ 0.002)
of 148 GWAS genes from across all 14 loci, including 46 GWAS genes whose proteins interact directly. Nodes for GWAS genes are color coded to indicate the
statistical significance of their connectivity within the network (scale is located in the upper-left-hand corner). The number of nodes with connectivity that is
weakly supported statistically may reflect the relatively small number of loci identified in AA (14), relative to other autoimmune diseases such as inflammatory
bowel disease, which has 163 GWAS loci (Jostins et al., 2012). AA, alopecia areata; GWAS, genome-wide association study.
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316In this study, we used three different
analytic techniques to discern etio-
logical processes encoded by GWAS
statistical evidence. In identifyingJournal of Investigative Dermatology (2016), Volumenriched pathways, biological processes,
and protein-protein interactions, 159 of
the 225 genes were implicated. Consis-
tent with evidence emerging frome 136systems biology studies in gene expres-
sion, our analyses identified multiple
genes at each loci (Table 1). The functions
of these genes converge on a limited
SUPPLEMENTARY MATERIAL
Supplementary material is linked to the online
version of the paper at www.jidonline.org, and at
http://dx.doi.org/10.1038/JID.2015.402.
C Hurabielle et al.
Se´zary Blood Markers in Erythrodermic Mycosis Fungoidesnumber of immunological pathways and
processes, for example, by identifying
antigen presentation and T-cell activation
and/or differentiation. Our results addi-
tionally underscore contributions from
the JAK-STAT signaling and the cos-
timulatory pathway. These particular
processes are capable of being modu-
lated with available therapeutics, which
we are currently studying within the
context of clinical trials in AA, using JAK
inhibitors and abatacept, respectively.
Furthermore, these genes could be useful
in our development of a biomarker panel,
allowing us to prioritize transcriptional
changes that occur over particular dis-
ease trajectories and/or during a thera-
peutic response. Finally, evidence
obtained in this study can be integrated
with results from next-generation
sequencing, providing a framework for
the interpretation of variants harbored by
patients and laying a foundation for pre-
cision medicine in AA.
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Se´zary syndrome (SS) and eryth-
rodermic mycosis fungoides (EMF) are
part of a broader spectrum of eryth-
rodermic cutaneous T-cell lymphoma.
The revised ISCL/EORTC staging iden-
tifies three types of blood involvement:
B0 (circulating Se´zary cells [CSC] 
5%), B1 (CSC > 5% but <1,000/mm3),
and B2 (CSC > 1,000/mm3) (Olsen
et al., 2007). Only B2 are recognized
as SS, whereas B0 and B1 are consid-
ered as EMF. EMF is defined as eryth-
roderma with papules and plaques
greater than 80% of the body surface
area associated with suggestive histol-
ogy of cutaneous T-cell lymphoma in
accordance with Olsen et al. However,patients with EMF must not meet SS
criteria, namely a CSC count > 1,000/
mm3, a CD4/CD8 ratio  10, a
CD4þCD7 lymphocyte population 
40%, or a CD4þCD26 population 
30% (Olsen et al., 2007; Willemze
et al., 2005). Several molecular
markers have been specifically identi-
fied in the blood of patients with SS,
including CD158k/KIR3DL2, the tran-
scription factor Twist, T-plastin (PLS3),
and CD335/NKp46 (Bensussan et al.,
2011; Bouaziz et al., 2010; Michel
et al., 2013; Nebozhyn et al., 2006;
Tang et al., 2010; Van Doorn et al.,
2004). Of interest, our previous results
clearly evidenced that their combina-
tion allows diagnosis of 100% ofuntreated patients with SS (Michel
et al., 2013).
Herein, this combination of blood
biomarkers was assessed in all the
patients with EMF diagnosed from
three French dermatological centers
during the last decade to determine
whether EMF covers a set of various
stages. To this aim, we compared pa-
tients with EMF with the cohort of
patients with SS (n ¼ 81, mean age
69.5 years [22e88 years]) and of
healthy donors (n ¼ 12, mean age
33.2 years [23e49 years]) previously
published (Michel et al., 2013). The
local ethics committees approved the
study and all the subjects gave written
informed consent. Thirty-one patients
were included (20 males, 11 women),
with a median age of 64.2 years
(30e85 years) at diagnosis: 13 patients
were B0 and 18 patients were B1, with
a mean  SD CSC absolute count ofwww.jidonline.org 317
